207_Combined course Presentations
RADITUX trial: final results
Overall Survival
OS was remarkably high (37% @ 5 years)
Hypofractionated RT + daily might contribute to increase OS in locally advanced NSCLC No positive results for Cetuximab and RT in stage III NSCLC so far
Median OS 33 (arm A) vs 30 (arm B) months p-value 0.722
Walraven I. et al. Radiot Oncol 2016;116
Made with FlippingBook